What has caused the massive slide in this stock over the past year? Both the immunotherapy low HER-2 expression and the oral diabetes spray sound promising. Any problems with these products or simply a revenue issue where nobody is sure when products will get approved? Dilution? Interesting thing about the immunotherapy is that it seems to potentially compete directly with GALE although GALE is just seeking to prevent recurrence rather than cure the initial tumors.
"What has caused the massive slide in this stock over the past year? "
I have this impression,while the market is going higher and higher,but actually less and less money behind it,running out of steam.Or the better scenario:the money inflow just became very very selective
"The other thing: FED ( or whoever) was pumping a bunch of stocks in the first 6 months of 2012.'
Just like CVM.BTW:how many GNBT shareholders posting on CVM board as well?How many of them hold GNBT as well?
Kind of complicated to guess,since Generex is not a company anybody can trust,they have long history of bulsheeting,not working,not delivering!
Basically they lost momentum in March,maybe in June as well..they did not meet FDA,they did not start phase 3,not like GALE.Now after that either the market "gave up" on them or they walked down the price (or both),who knows.The usual "selling new shares below market price" did not help either.In this moment not much chance for anything ( no money and not much "desire" to work..as usual)unless they know something what we don't
AE37 is definitely aiming to compete directly with GALE. Literally the same mechanism of action to do the same thing - prevent recurrence of HER2 negative cancer in patients for which it has already spread to the lymph nodes by stimulating the immune system. However, GALE will have its PH3 study done in about 2 years. Anyone have any thoughts on that. I am going to have to do some digging into the mechanism of action. I was always going to go back to GALE, but this seems like an important DD issue.